You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Potent, competitive and selective inhibitor of glutamate uptake. Certain confusion exists over the naming of this compound because of apparent contradictions in the literature. This is the isomer which has the carboxylic acid and the amino groups on the same side of the cyclobutyl ring.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 159.14. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||6.28 mL||31.42 mL||62.84 mL|
|5 mM||1.26 mL||6.28 mL||12.57 mL|
|10 mM||0.63 mL||3.14 mL||6.28 mL|
|50 mM||0.13 mL||0.63 mL||1.26 mL|
References are publications that support the biological activity of the product.
Allan et al (1990) Synthesis and activity of a potent NMDA agonist, trans-1-aminocyclobutane-1,3-dicarboxylic acid, and related phosphonic and carboxylic acids. J.Med.Chem. 33 2905 PMID: 2145435
Fletcher et al (1991) Inhibition of L-glutamic acid uptake into rat cortical synaptosomes by the conformationally restricted analogue of glutamic acid, cis-1-aminocyclobutane-1,3-dicarboxylic acid. Neurosci.Lett. 121 133 PMID: 1673544
Koch et al (1999) Differentiation of substrate and nonsubstrate inhibitors of the high-affinity, sodium-dependent glutamate transporters. Mol.Pharmacol. 56 1095 PMID: 10570036
If you know of a relevant reference for cis-ACBD, please let us know.
View Related Products by Product Action
Keywords: cis-ACBD, cis-ACBD supplier, Potent, selective, competitive, L-glutamate, uptake, inhibitors, inhibits, EAAT, Excitatory, Amino, Acid, Transporters, GLAST, GLT-1, Glutamate, Monoamine, Neurotransmitter, 0271, Tocris Bioscience
1 Citation for cis-ACBD
Citations are publications that use Tocris products. Selected citations for cis-ACBD include:
Lee et al (2010) Characterisation of the expression of NMDA receptors in human astrocytes. PLoS One 5 e14123 PMID: 21152063
Do you know of a great paper that uses cis-ACBD from Tocris? Please let us know.
Reviews for cis-ACBD
There are currently no reviews for this product. Be the first to review cis-ACBD and earn rewards!
Have you used cis-ACBD?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.